Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Stem Cell Therapeutics Acquires Complementary Antibody Program

Published: Thursday, October 17, 2013
Last Updated: Thursday, October 17, 2013
Bookmark and Share
The company has entered into an option agreement to exclusively license worldwide rights to a panel of fully human monoclonal antibodies targeting the SIRPa protein (CD172a).

The technology was developed by scientists at the University Health Network, the University of Toronto, through the Toronto Recombinant Antibody Centre (TRAC), and The Hospital for Sick Children (SickKids), in Toronto, Ontario. 

SIRPa is the ligand of CD47, a molecule upregulated on many hematological and solid tumors. CD47 delivers a “do not eat” signal that suppresses macrophage phagocytosis, allowing cancer cells, including cancer stem cells, to escape immune-mediated destruction. Stem Cell Therapeutics (SCT) is currently developing a CD47 antagonist, using a modified version of the native SIRPa protein fused to an immunoglobulin Fc region. This SIRPaFc fusion protein has shown remarkable anti-leukemic activity both in vitro and in human xenograft models, and SCT recently announced that the program has entered the IND-enabling phase of drug development. The company expects to report further updates at the upcoming annual meeting of the American Society of Hematology (December 7-10, 2013). 

“Targeting the CD47/SIRPa pathway can eliminate both bulk cancer cells and cancer stem cells, and engages both the innate and the adaptive arms of the immune system,” commented SCT’s Chief Scientific Officer, Dr. Bob Uger. “Antibody blockade of SIRPa is a promising approach to activate the anti-tumor activity of macrophages against both liquid and solid tumors, and has the potential as both a monotherapy and combination therapy with other anti-cancer antibodies.” 

“The CD47/SIRPa axis is one of the most promising and compelling next-generation immunotherapy targets in the fight against cancer,” remarked SCT’s Chief Executive -2- Officer, Dr. Niclas Stiernholm. “Having recently announced the advancement of our SIRPaFc program into formal IND-enabling studies, a program we believe is the best-inclass CD47 antagonist currently in development, reinforcing our industry-leading position in this pathway with a complementary antibody program against the SIRPa protein makes eminent sense.” 

The execution of the definitive license agreement is subject to final due-diligence and certain conditions being met by SCT over the next nine months. The license agreement will contain customary terms and provisions for assets at this stage of development, including an initial license consideration, milestone payments, royalties on sales and sublicensing terms. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCT to Provide Update on CD47 Program at the 2014 AACR Annual Meeting
Announcing a key difference between SIRPaFc and other CD47-blocking agents.
Friday, April 04, 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Adds US industry veterans with broad financial and clinical expertise.
Tuesday, March 11, 2014
Stem Cell Therapeutics Announces Resignation of Director
Mr. David Allan has resigned from Company’s board of directors.
Thursday, January 30, 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.
Thursday, January 30, 2014
Stem Cell Therapeutics Provides Corporate Update
Company provides six-month corporate update.
Monday, January 20, 2014
Stem Cell Therapeutics Completes $33 Million Private Placement
Financing proceeds used to advance the Company’s CD47 cancer stem cell program.
Friday, December 20, 2013
Stem Cell Therapeutics Appoints Dr. Robert Kirkman to its Board of Directors
Provides update on $33 million offering.
Wednesday, December 18, 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation
Company receives drug designation for the use of tigecycline to treat AML.
Friday, November 01, 2013
Stem Cell Therapeutics Advances CD47 Antagonist Program into Ind-Enabling Phase
Stem Cell Therapeutics Corp. announced that it has advanced its CD47 antagonist program into an Investigational New Drug (IND) enabling phase.
Monday, September 09, 2013
SCT Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets
Collaboration with internationally renowned prostate cancer research group.
Monday, August 12, 2013
SCT Licenses Exclusive Rights to Clinical Cancer Stem Cell Program
Corporate refocusing mission completed.
Friday, April 19, 2013
SCT Announces Joint-Venture Agreement with Reneu and Nexgen
Company to move the combined technologies into clinical trials with a target of clinical initiation in 2014.
Wednesday, February 20, 2013
SCT Announces Agreement with Trillium for Merger
Continuing Stem Cell Therapeutics' commitment to expansion.
Wednesday, February 06, 2013
Stem Cell Therapeutics Announces Agreement with UHN and MaRS Innovation
Building on the continued strength of Canadian stem cell research.
Thursday, November 08, 2012
Scientific News
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Muscles on-a-Chip
This study may help explain why stem cell-based therapies have so far shown limited benefits for heart attack patients in clinical trials.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cat Stem Cell Therapy Gives Humans Hope
By the time Bob the cat came to the UC Davis veterinary hospital, he had used up most of his nine lives.
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Edited Stem Cells Offer Hope of Precision Therapy for Blindness
Findings raise the possibility of treating blinding eye diseases using a patient's own corrected cells as replacement tissue.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!